{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T04:03:43Z","timestamp":1785643423409,"version":"3.56.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Intranasal agents may be ideal for the treatment of migraine patients. Many new acute intranasal-specific therapies have been developed, but few of them have been directly compared. The aim of this network meta-analysis (NMA) was to compare the efficacy and safety of various intranasal agents for the treatment of acute migraine in adult patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The Cochrane Register of Controlled Trials, Embase, and PubMed were searched from inception to 15 August 2023. Randomized controlled trials (RCTs) using intranasal agents (no restrictions on dose, formulation, dosing regimen or timing of the first dose) to treat adult patients with acute migraine were included. The primary efficacy endpoint was pain freedom at 2\u00a0h, and the primary safety endpoint was adverse events (AEs). The analysis process followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Nineteen studies (21 RCTs, 9738 participants) were included. Compared to the placebo, 5\u00a0mg of zolmitriptan using a conventional liquid nasal spray device was the most effective for pain freedom at 2\u00a0h [odds ratio (OR): 4.67, 95% confidence interval (CI): 3.43 to 6.43] and 24\u00a0h (OR: 5.49, 95% CI: 3.58 to 8.42) among all the interventions. Butorphanol nasal spray 1\u00a0mg was the most effective (OR: 8.62, 95% CI: 1.11 to 66.92) for pain freedom at 1\u00a0h, but with low-quality evidence. DFN-02 presented the highest freedom from nausea (OR: 4.95, 95% CI: 1.29 to 19.01) and phonophobia (OR: 5.36, 95% CI: 1.67 to 17.22) at 2\u00a0h, albeit with lower odds of achieving complete pain freedom. ROX-828 showed the highest improvement in freedom from photophobia at 2\u00a0h (OR: 4.03, 95% CI: 1.66 to 9.81). Dihydroergotamine nasal spray was significantly associated with the highest risk of AEs (OR: 9.65, 95% CI: 4.39 to 21.22) and was not recommended for routine use. Zavegepant nasal spray demonstrated the lowest risk of AEs (OR: 2.04, 95% CI: 1.37 to 3.03). The results of sensitivity analyses for the primary endpoints (pain freedom at 2\u00a0h and AEs) were generally consistent with those of the base case model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Compared with other new intranasal-specific therapies in treating migraine attacks, zolmitriptan nasal spray 5\u00a0mg was the most effective agent for pain freedom at 2\u00a0h. Zavegepant nasal spray 10\u00a0mg had the fewest adverse side effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-023-01662-6","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T08:02:07Z","timestamp":1695024127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Guanglu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojie","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"issue":"4","key":"1662_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S1474-4422(08)70062-0","volume":"7","author":"R Jensen","year":"2008","unstructured":"Jensen R, Stovner LJ (2008) Epidemiology and comorbidity of headache. Lancet Neurol 7(4):354\u2013361","journal-title":"Lancet Neurol"},{"issue":"4","key":"1662_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJMra010917","volume":"346","author":"PJ Goadsby","year":"2002","unstructured":"Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine\u2013current understanding and treatment. N Engl J Med 346(4):257\u2013270","journal-title":"N Engl J Med"},{"issue":"1","key":"1662_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41572-021-00328-4","volume":"8","author":"MD Ferrari","year":"2022","unstructured":"Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A, Ashina M, van den Maagdenberg Amjm, Dodick DW (2022) Migraine. Nat Rev Dis Primers. 8(1):2","journal-title":"Nat Rev Dis Primers."},{"issue":"9859","key":"1662_CR4","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0140-6736(12)61680-8","volume":"380","author":"JA Salomon","year":"2012","unstructured":"Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, Begum N, Shah R, Karyana M, Kosen S, Farje MR, Moncada G, Dutta A, Sazawal S, Dyer A, Seiler J, Aboyans V, Baker L, Baxter A, Benjamin EJ, Bhalla K, Bin AA, Blyth F, Bourne R, Braithwaite T, Brooks P, Brugha TS, Bryan-Hancock C, Buchbinder R, Burney P, Calabria B, Chen H, Chugh SS, Cooley R, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, Davis A, Degenhardt L, Diaz-Torne C, Dorsey ER, Driscoll T, Edmond K, Elbaz A, Ezzati M, Feigin V, Ferri CP, Flaxman AD, Flood L, Fransen M, Fuse K, Gabbe BJ, Gillum RF, Haagsma J, Harrison JE, Havmoeller R, Hay RJ, Hel-Baqui A, Hoek HW, Hoffman H, Hogeland E, Hoy D, Jarvis D, Karthikeyan G, Knowlton LM, Lathlean T, Leasher JL, Lim SS, Lipshultz SE, Lopez AD, Lozano R, Lyons R, Malekzadeh R, Marcenes W, March L, Margolis DJ, Mcgill N, Mcgrath J, Mensah GA, Meyer AC, Michaud C, Moran A, Mori R, Murdoch ME, Naldi L, Newton CR, Norman R, Omer SB, Osborne R, Pearce N, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Pourmalek F, Prince M, Rehm JT, Remuzzi G, Richardson K, Room R, Saha S, Sampson U, Sanchez-Riera L, Segui-Gomez M, Shahraz S, Shibuya K, Singh D, Sliwa K, Smith E, Soerjomataram I, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Taylor HR, Tleyjeh IM, van der Werf MJ, Watson WL, Weatherall DJ, Weintraub R, Weisskopf MG, Whiteford H, Wilkinson JD, Woolf AD, Zheng ZJ (2012) CJ. Murray, and JB Jonas Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 380(9859):2129\u201343","journal-title":"Lancet"},{"key":"1662_CR5","doi-asserted-by":"publisher","unstructured":"(2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edn. Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"1662_CR6","unstructured":"GBD 2015 Neurological Disorders Collaborator Group (2017) Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 16(11):877\u2013897"},{"issue":"2","key":"1662_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jamaneurol.2020.4152","volume":"78","author":"VL Feigin","year":"2021","unstructured":"Feigin VL, Vos T, Alahdab F, Amit A, Barnighausen TW, Beghi E, Beheshti M, Chavan PP, Criqui MH, Desai R, Dhamminda DS, Dorsey ER, Eagan A, Wilder IY, Elgendy I, Filip S, Giampaoli G, Giussani N, Hafezi-Nejad MK, Hole T, Ikeda JC, Owens R, Kalani K, Khatab J, Khubchandani D, Kim WJ, Koroshetz V, Krishnamoorthy RV, Krishnamurthi X, Liu WD, Lo G, Logroscino GA, Mensah TR, Miller S, Mohammed AH, Mokdad M, Moradi-Lakeh SD, Morrison V, Shivamurthy M, Naghavi E, Nichols B, Norrving CM, Odell E, Pupillo A, Radfar GA, Roth A, Shafieesabet A, Sheikh S, Sheikhbahaei JI, Shin JA, Singh TJ, Steiner LJ, Stovner MT, Wallin J, Weiss C, Wu JR, Zunt JD (2021) Adelson, and Cjl Murray Burden of Neurological Disorders Across the US From 1990\u20132017: A Global Burden of Disease Study. JAMA Neurol. 78(2):165\u2013176","journal-title":"JAMA Neurol."},{"issue":"1","key":"1662_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21(1):137","journal-title":"J Headache Pain"},{"key":"1662_CR9","unstructured":"GBD 2016 Neurology Collaborators (2019) Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(5):459\u2013480"},{"issue":"11","key":"1662_CR10","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1177\/0333102414566200","volume":"35","author":"YW Woldeamanuel","year":"2015","unstructured":"Woldeamanuel YW, Rapoport AM, Cowan RP (2015) The place of corticosteroids in migraine attack management: a 65-year systematic review with pooled analysis and critical appraisal. Cephalalgia 35(11):996\u20131024","journal-title":"Cephalalgia"},{"issue":"5","key":"1662_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10194-012-0460-7","volume":"13","author":"LM Bloudek","year":"2012","unstructured":"Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, Varon SF, Blumenfeld AM, Katsarava Z, Pascual J, Lanteri-Minet M, Cortelli P, Martelletti P (2012) Cost of healthcare for patients with migraine in five european countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain 13(5):361\u2013378","journal-title":"J Headache Pain"},{"issue":"5 Suppl 3","key":"1662_CR12","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1017\/S0317167100118943","volume":"40","author":"I Worthington","year":"2013","unstructured":"Worthington I, Pringsheim T, Gawel MJ, Gladstone J, Cooper P, Dilli E, Aube M, Leroux E, Becker WJ (2013) Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci 40(5 Suppl 3):S1\u2013S80","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"1662_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/head.12499","volume":"55","author":"MJ Marmura","year":"2015","unstructured":"Marmura MJ, Silberstein SD, Schwedt TJ (2015) The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache 55(1):3\u201320","journal-title":"Headache"},{"issue":"20","key":"1662_CR14","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1001\/jama.284.20.2599","volume":"284","author":"RB Lipton","year":"2000","unstructured":"Lipton RB, Stewart WF, Stone AM, Lainez MJ, Sawyer JP (2000) Stratified care vs step care strategies for migraine: the disability in strategies of care (DISC) study: a randomized trial. JAMA 284(20):2599\u20132605","journal-title":"JAMA"},{"issue":"10127","key":"1662_CR15","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0140-6736(18)30478-1","volume":"391","author":"DW Dodick","year":"2018","unstructured":"Dodick DW (2018) Migraine Lancet 391(10127):1315\u20131330","journal-title":"Migraine Lancet"},{"key":"1662_CR16","first-page":"322","volume":"47","author":"I Worthington","year":"2001","unstructured":"Worthington I (2001) Delivery systems for acute migraine medications. Can Fam Physician 47:322\u2013329","journal-title":"Can Fam Physician"},{"issue":"8","key":"1662_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/17512433.2017.1339600","volume":"10","author":"S Silberstein","year":"2017","unstructured":"Silberstein S (2017) AVP-825: a novel intranasal delivery system for low-dose sumatriptan powder in the treatment of acute migraine. Expert Rev Clin Pharmacol 10(8):821\u2013832","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"1662_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1526-4610.1995.hed3507387.x","volume":"35","author":"SD Silberstein","year":"1995","unstructured":"Silberstein SD (1995) Migraine symptoms: results of a survey of self-reported migraineurs. Headache 35(7):387\u2013396","journal-title":"Headache"},{"issue":"1","key":"1662_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1526-4610.2006.00311.x","volume":"46","author":"SK Aurora","year":"2006","unstructured":"Aurora SK, Kori SH, Barrodale P, Mcdonald SA, Haseley D (2006) Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache 46(1):57\u201363","journal-title":"Headache"},{"issue":"7","key":"1662_CR20","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/acem.14208","volume":"28","author":"C Lim","year":"2021","unstructured":"Lim C, Singh M (2021) Subcutaneous sumatriptans for acute migraine attacks in adults. Acad Emerg Med 28(7):814\u2013815","journal-title":"Acad Emerg Med"},{"issue":"2","key":"1662_CR21","first-page":"CD009665","volume":"2012","author":"CJ Derry","year":"2012","unstructured":"Derry CJ, Derry S, Moore RA (2012) Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012(2):CD009665","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1662_CR22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/head.12835","volume":"56","author":"SL Orr","year":"2016","unstructured":"Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, Tepper D (2016) Management of adults with Acute Migraine in the Emergency Department: the american Headache Society evidence Assessment of Parenteral Pharmacotherapies. Headache 56(6):911\u2013940","journal-title":"Headache"},{"issue":"16","key":"1662_CR23","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1517\/14656566.2012.730041","volume":"13","author":"L Lionetto","year":"2012","unstructured":"Lionetto L, Negro A, Casolla B, Simmaco M, Martelletti P (2012) Sumatriptan succinate: pharmacokinetics of different formulations in clinical practice. Expert Opin Pharmacother 13(16):2369\u20132380","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1662_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-018-0881-z","volume":"19","author":"S Landy","year":"2018","unstructured":"Landy S, Munjal S, Brand-Schieber E, Rapoport AM (2018) Efficacy and safety of DFN-11 (sumatriptan injection, 3\u00a0mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study. J Headache Pain 19(1):69","journal-title":"J Headache Pain"},{"key":"1662_CR25","unstructured":"IMITREX (sumatriptan succinate. Injection prescribing information. 2019, Available at: https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Imitrex_Injection\/pdf\/IMITREX-INJECTION-PI-PPI-PIL-COMBINED.PDF. Accessed 12"},{"issue":"1","key":"1662_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1046\/j.1526-4610.2003.03006.x","volume":"43","author":"RM Gallagher","year":"2003","unstructured":"Gallagher RM, Kunkel R (2003) Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 43(1):36\u201343","journal-title":"Headache"},{"issue":"7","key":"1662_CR27","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1185\/03007995.2012.674501","volume":"28","author":"K Erlichson","year":"2012","unstructured":"Erlichson K, Waight J (2012) Therapeutic applications for subcutaneous triptans in the acute treatment of migraine. Curr Med Res Opin 28(7):1231\u20131238","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"1662_CR28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, Pozo-Rosich P, Martelletti P, Ducros A, Lanteri-Minet M, Braschinsky M, Del RM, Daniel O, Ozge A, Mammadbayli A, Arons M, Skorobogatykh K, Romanenko V, Terwindt GM, Paemeleire K, Sacco S, Reuter U, Lampl C, Schytz HW, Katsarava Z, Steiner TJ, Ashina M (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17(8):501\u2013514","journal-title":"Nat Rev Neurol"},{"issue":"19","key":"1662_CR29","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M (2020) Migraine. N Engl J Med 383(19):1866\u20131876","journal-title":"N Engl J Med"},{"issue":"4","key":"1662_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11910-020-01030-w","volume":"20","author":"J Robblee","year":"2020","unstructured":"Robblee J, Grimsrud KW (2020) Emergency Department and Inpatient Management of Headache in adults. Curr Neurol Neurosci Rep 20(4):7","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"7","key":"1662_CR31","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097","journal-title":"PLoS Med"},{"issue":"1","key":"1662_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10072-017-3119-y","volume":"39","author":"A Menshawy","year":"2018","unstructured":"Menshawy A, Ahmed H, Ismail A, Abushouk AI, Ghanem E, Pallanti R, Negida A (2018) Intranasal sumatriptan for acute migraine attacks: a systematic review and meta-analysis. Neurol Sci 39(1):31\u201344","journal-title":"Neurol Sci"},{"issue":"7","key":"1662_CR33","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1080\/14737175.2016.1195687","volume":"16","author":"FG Freitag","year":"2016","unstructured":"Freitag FG, Shumate DA (2016) The efficacy and safety of sumatriptan intranasal powder in adults with acute migraine. Expert Rev Neurother 16(7):743\u2013747","journal-title":"Expert Rev Neurother"},{"issue":"5","key":"1662_CR34","first-page":"CD009108","volume":"2014","author":"CJ Derry","year":"2014","unstructured":"Derry CJ, Derry S, Moore RA (2014) Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Cochrane Database Syst Rev 2014(5):CD009108","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1662_CR35","first-page":"CD008616","volume":"2014","author":"S Bird","year":"2014","unstructured":"Bird S, Derry S, Moore RA (2014) Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst Rev 2014(5):CD008616","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1662_CR36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/0333102419828967","volume":"39","author":"HC Diener","year":"2019","unstructured":"Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J (2019) Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: fourth edition. Cephalalgia 39(6):687\u2013710","journal-title":"Cephalalgia"},{"key":"1662_CR37","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"J Sterne, Jac","year":"2019","unstructured":"Sterne, Jac J, Savovic MJ, Page RG, Elbers NS, Blencowe I, Boutron CJ, Cates HY, Cheng MS, Corbett SM, Eldridge JR, Emberson MA, Hernan S, Hopewell A, Hrobjartsson DR, Junqueira P, Juni JJ, Kirkham T, Lasserson T, Li A, Mcaleenan BC, Reeves S, Shepperd I, Shrier LA, Stewart K, Tilling IR, White PF, Whiting, Higgins J (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"issue":"4","key":"1662_CR38","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1058","volume":"3","author":"G Rucker","year":"2012","unstructured":"Rucker G (2012) Network meta-analysis, electrical networks and graph theory. Res Synth Methods 3(4):312\u2013324","journal-title":"Res Synth Methods"},{"issue":"25","key":"1662_CR39","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1002\/sim.6236","volume":"33","author":"G Rucker","year":"2014","unstructured":"Rucker G, Schwarzer G (2014) Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis. Stat Med 33(25):4353\u20134369","journal-title":"Stat Med"},{"issue":"7414","key":"1662_CR40","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"7\u20138","key":"1662_CR41","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM (2010) Ades AEChecking consistency in mixed treatment comparison meta-analysis. Stat Med. 29(7\u20138):932\u201344","journal-title":"Stat Med."},{"issue":"3","key":"1662_CR42","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/jebm.12443","volume":"14","author":"J Tian","year":"2021","unstructured":"Tian J, Gao Y, Zhang J, Yang Z, Dong S, Zhang T, Sun F, Wu S, Wu J, Wang J, Yao L, Ge L, Li L, Shi C, Wang Q, Li J, Zhao Y, Xiao Y, Yang F, Fan J, Bao S, Song F (2021) Progress and challenges of network meta-analysis. J Evid Based Med 14(3):218\u2013231","journal-title":"J Evid Based Med"},{"issue":"1","key":"1662_CR43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T (2017) Network meta-analysis: an introduction for clinicians. Intern Emerg Med 12(1):103\u2013111","journal-title":"Intern Emerg Med"},{"issue":"2","key":"1662_CR44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64(2):163\u2013171","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1662_CR45","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12874-021-01397-5","volume":"21","author":"KJ Rosenberger","year":"2021","unstructured":"Rosenberger KJ, Duan R, Chen Y, Lin L (2021) Predictive P-score for treatment ranking in bayesian network meta-analysis. BMC Med Res Methodol 21(1):213","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"1662_CR46","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins J, Papakonstantinou T, Chaimani A, Del GC, Egger M, Salanti G (2020) CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med 17(4):e1003082","journal-title":"PLoS Med"},{"key":"1662_CR47","doi-asserted-by":"publisher","unstructured":"Papakonstantinou T, Nikolakopoulou A, Higgins J, Egger M, Salanti G (2020) CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Syst Rev 16(1):e1080.\u00a0https:\/\/doi.org\/10.1002\/cl2.1080","DOI":"10.1002\/cl2.1080"},{"issue":"10","key":"1662_CR48","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G (2013) Graphical tools for network meta-analysis in STATA. PLoS ONE 8(10):e76654","journal-title":"PLoS ONE"},{"issue":"3","key":"1662_CR49","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","volume":"22","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Croop R, Stock DA, Madonia J, Forshaw M, Lovegren M, Mosher L, Coric V, Goadsby PJ (2023) Safety, tolerability, and efficacy of zavegepant 10\u00a0mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol 22(3):209\u2013217","journal-title":"Lancet Neurol"},{"issue":"9","key":"1662_CR50","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/head.14389","volume":"62","author":"R Croop","year":"2022","unstructured":"Croop R, Madonia J, Stock DA, Thiry A, Forshaw M, Murphy A, Coric V, Lipton RB (2022) Zavegepant nasal spray for the acute treatment of migraine: a phase 2\/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache 62(9):1153\u20131163","journal-title":"Headache"},{"issue":"5","key":"1662_CR51","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/head.13309","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Munjal S, Brand-Schieber E, Rapoport AM (2018) DFN-02 (Sumatriptan 10\u00a0mg with a permeation enhancer) nasal spray vs placebo in the Acute treatment of migraine: a Double-Blind, placebo-controlled study. Headache 58(5):676\u2013687","journal-title":"Headache"},{"issue":"2","key":"1662_CR52","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/head.12767","volume":"56","author":"AS Rao","year":"2016","unstructured":"Rao AS, Gelaye B, Kurth T, Dash PD, Nitchie H, Peterlin BL (2016) A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine. Headache 56(2):331\u2013340","journal-title":"Headache"},{"issue":"1","key":"1662_CR53","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/head.12472","volume":"55","author":"RK Cady","year":"2015","unstructured":"Cady RK, Mcallister PJ, Spierings EL, Messina J, Carothers J, Djupesland PG, Mahmoud RA (2015) A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (the TARGET study). Headache 55(1):88\u2013100","journal-title":"Headache"},{"issue":"10","key":"1662_CR54","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1177\/0333102412451359","volume":"32","author":"V Pfaffenrath","year":"2012","unstructured":"Pfaffenrath V, Fenzl E, Bregman D, Farkkila M (2012) Intranasal ketorolac tromethamine (SPRIX(R)) containing 6% of lidocaine (ROX-828) for acute treatment of migraine: safety and efficacy data from a phase II clinical trial. Cephalalgia 32(10):766\u2013777","journal-title":"Cephalalgia"},{"issue":"4","key":"1662_CR55","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1526-4610.2011.01869.x","volume":"51","author":"SK Aurora","year":"2011","unstructured":"Aurora SK, Silberstein SD, Kori SH, Tepper SJ, Borland SW, Wang M, Dodick DW (2011) MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache 51(4):507\u2013517","journal-title":"Headache"},{"issue":"8","key":"1662_CR56","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1177\/0333102409359314","volume":"30","author":"PG Djupesland","year":"2010","unstructured":"Djupesland PG, Docekal P (2010) Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study. Cephalalgia 30(8):933\u2013942","journal-title":"Cephalalgia"},{"issue":"6","key":"1662_CR57","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1526-4610.2009.01453.x","volume":"49","author":"SK Aurora","year":"2009","unstructured":"Aurora SK, Rozen TD, Kori SH, Shrewsbury SB (2009) A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 49(6):826\u2013837","journal-title":"Headache"},{"issue":"2","key":"1662_CR58","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1726-4901(09)70300-4","volume":"70","author":"SJ Wang","year":"2007","unstructured":"Wang SJ, Fuh JL, Wu ZA (2007) Intranasal sumatriptan study with high placebo response in taiwanese patients with migraine. J Chin Med Assoc 70(2):39\u201346","journal-title":"J Chin Med Assoc"},{"issue":"2","key":"1662_CR59","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2165\/00023210-200519020-00003","volume":"19","author":"D Dodick","year":"2005","unstructured":"Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L (2005) Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs 19(2):125\u2013136","journal-title":"CNS Drugs"},{"issue":"1","key":"1662_CR60","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1526-4610.2005.05004.x","volume":"45","author":"M Gawel","year":"2005","unstructured":"Gawel M, Aschoff J, May A, Charlesworth BR (2005) Zolmitriptan 5\u00a0mg nasal spray: efficacy and onset of action in the acute treatment of migraine\u2013results from phase 1 of the REALIZE Study. Headache 45(1):7\u201316","journal-title":"Headache"},{"issue":"9","key":"1662_CR61","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2165\/00023210-200317090-00005","volume":"17","author":"BR Charlesworth","year":"2003","unstructured":"Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, F\u76f2rkkil\u76f2 M (2003) Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 17(9):653\u2013667","journal-title":"CNS Drugs"},{"issue":"1","key":"1662_CR62","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1046\/j.1468-1331.1999.610043.x","volume":"6","author":"A Peikert","year":"1999","unstructured":"Peikert A, Becker WJ, Ashford EA, Dahlof C, Hassani H, Salonen RJ (1999) Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine. Eur J Neurol 6(1):43\u201349","journal-title":"Eur J Neurol"},{"issue":"3","key":"1662_CR63","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/archfami.7.3.234","volume":"7","author":"S Diamond","year":"1998","unstructured":"Diamond S, Elkind A, Jackson RT, Ryan R, Debussey S, Asgharnejad M (1998) Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med 7(3):234\u2013240","journal-title":"Arch Fam Med"},{"issue":"5","key":"1662_CR64","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1212\/WNL.49.5.1225","volume":"49","author":"R Ryan","year":"1997","unstructured":"Ryan R, Elkind A, Baker CC, Mullican W, Debussey S, Asgharnejad M (1997) Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology 49(5):1225\u20131230","journal-title":"Neurology"},{"issue":"12","key":"1662_CR65","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1001\/archneur.1996.00550120097022","volume":"53","author":"RM Gallagher","year":"1996","unstructured":"Gallagher RM (1996) Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group Arch Neurol 53(12):1285\u20131291","journal-title":"Dihydroergotamine Working Group Arch Neurol"},{"issue":"2","key":"1662_CR66","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1526-4610.1995.hed3502065.x","volume":"35","author":"MJ Hoffert","year":"1995","unstructured":"Hoffert MJ, Couch JR, Diamond S, Elkind AH, Goldstein J, Kohlerman NR, Saper JR, Solomon S (1995) Transnasal butorphanol in the treatment of acute migraine. Headache 35(2):65\u201369","journal-title":"Headache"},{"issue":"8","key":"1662_CR67","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/BF00919706","volume":"241","author":"R Salonen","year":"1994","unstructured":"Salonen R, Ashford E, Dahlof C, Dawson R, Gilhus NE, Luben V, Noronha D, Warter JM (1994) Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group. J Neurol 241(8):463\u2013469","journal-title":"J Neurol"},{"issue":"8","key":"1662_CR68","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1046\/j.1468-2982.1998.1808532.x","volume":"18","author":"P Tfelt-Hansen","year":"1998","unstructured":"Tfelt-Hansen P (1998) Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 18(8):532\u2013538","journal-title":"Cephalalgia"},{"issue":"9","key":"1662_CR69","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/head.12905","volume":"56","author":"S Munjal","year":"2016","unstructured":"Munjal S, Gautam A, Offman E, Brand-Schieber E, Allenby K, Fisher DM (2016) A Randomized Trial comparing the Pharmacokinetics, Safety, and tolerability of DFN-02, an Intranasal Sumatriptan Spray containing a permeation enhancer, with Intranasal and Subcutaneous Sumatriptan in healthy adults. Headache 56(9):1455\u20131465","journal-title":"Headache"},{"issue":"1","key":"1662_CR70","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","volume":"3","author":"PG Djupesland","year":"2013","unstructured":"Djupesland PG (2013) Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res 3(1):42\u201362","journal-title":"Drug Deliv Transl Res"},{"issue":"6","key":"1662_CR71","doi-asserted-by":"publisher","first-page":"709","DOI":"10.4155\/tde.14.41","volume":"5","author":"PG Djupesland","year":"2014","unstructured":"Djupesland PG, Messina JC, Mahmoud RA (2014) The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther Deliv 5(6):709\u2013733","journal-title":"Ther Deliv"},{"issue":"1","key":"1662_CR72","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1526-4610.2006.00301.x","volume":"46","author":"PJ Goadsby","year":"2006","unstructured":"Goadsby PJ, Yates R (2006) Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy. Headache 46(1):138\u2013149","journal-title":"Headache"},{"issue":"11","key":"1662_CR73","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2165\/00003088-200241110-00002","volume":"41","author":"E Fuseau","year":"2002","unstructured":"Fuseau E, Petricoul O, Moore KH, Barrow A, Ibbotson T (2002) Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet 41(11):801\u2013811","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"1662_CR74","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/head.12167","volume":"53","author":"M Obaidi","year":"2013","unstructured":"Obaidi M, Offman E, Messina J, Carothers J, Djupesland PG, Mahmoud RA (2013) Improved pharmacokinetics of sumatriptan with Breath powered nasal delivery of sumatriptan powder. Headache 53(8):1323\u20131333","journal-title":"Headache"},{"issue":"5","key":"1662_CR75","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/head.12583","volume":"55","author":"SJ Tepper","year":"2015","unstructured":"Tepper SJ, Cady RK, Silberstein S, Messina J, Mahmoud RA, Djupesland PG, Shin P, Siffert J (2015) AVP-825 breath-powered intranasal delivery system containing 22\u00a0mg sumatriptan powder vs 100\u00a0mg oral sumatriptan in the acute treatment of migraines (the COMPASS study): a comparative randomized clinical trial across multiple attacks. Headache 55(5):621\u2013635","journal-title":"Headache"},{"issue":"1","key":"1662_CR76","first-page":"40","volume":"60","author":"SD Silberstein","year":"2020","unstructured":"Silberstein SD, Shrewsbury SB, Hoekman J (2020) Dihydroergotamine (DHE) - then and now. Narrative Rev Headache 60(1):40\u201357","journal-title":"Narrative Rev Headache"},{"issue":"Suppl 4","key":"1662_CR77","first-page":"S212","volume":"46","author":"JR Saper","year":"2006","unstructured":"Saper JR, Silberstein S, Dodick D (2006) Rapoport ADHE in the pharmacotherapy of migraine: potential for a larger role. Headache. 46(Suppl 4):S212\u2013S220","journal-title":"Headache."},{"issue":"8","key":"1662_CR78","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/head.12166","volume":"53","author":"SJ Tepper","year":"2013","unstructured":"Tepper SJ (2013) Clinical implications for breath-powered powder sumatriptan intranasal treatment. Headache 53(8):1341\u20131349","journal-title":"Headache"},{"issue":"12","key":"1662_CR79","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1185\/03007995.2012.744302","volume":"28","author":"A He","year":"2012","unstructured":"He A, Hersh EV (2012) A review of intranasal ketorolac tromethamine for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. Curr Med Res Opin 28(12):1873\u20131880","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"1662_CR80","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/j.1526-4637.2009.00647.x","volume":"10","author":"C Brown","year":"2009","unstructured":"Brown C, Moodie J, Bisley E, Bynum L (2009) Intranasal ketorolac for postoperative pain: a phase 3, double-blind, randomized study. Pain Med 10(6):1106\u20131114","journal-title":"Pain Med"},{"issue":"6","key":"1662_CR81","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1213\/ane.0b013e318188b736","volume":"107","author":"JE Moodie","year":"2008","unstructured":"Moodie JE, Brown CR, Bisley EJ, Weber HU, Bynum L (2008) The safety and analgesic efficacy of intranasal ketorolac in patients with postoperative pain. Anesth Analg 107(6):2025\u20132031","journal-title":"Anesth Analg"},{"issue":"5","key":"1662_CR82","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.joms.2009.10.023","volume":"68","author":"GM Grant","year":"2010","unstructured":"Grant GM, Mehlisch DR (2010) Intranasal ketorolac for pain secondary to third molar impaction surgery: a randomized, double-blind, placebo-controlled trial. J Oral Maxillofac Surg 68(5):1025\u20131031","journal-title":"J Oral Maxillofac Surg"},{"issue":"10","key":"1662_CR83","doi-asserted-by":"publisher","first-page":"e0224285","DOI":"10.1371\/journal.pone.0224285","volume":"14","author":"PW Chi","year":"2019","unstructured":"Chi PW, Hsieh KY, Chen KY, Hsu CW, Bai CH, Chen C, Hsu YP (2019) Intranasal lidocaine for acute migraine: a meta-analysis of randomized controlled trials. PLoS ONE 14(10):e0224285","journal-title":"PLoS ONE"},{"issue":"2","key":"1662_CR84","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ (2019) Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for Migraine. N Engl J Med 381(2):142\u2013149","journal-title":"N Engl J Med"},{"issue":"19","key":"1662_CR85","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM (2019) Effect of Ubrogepant vs Placebo on Pain and the most Bothersome Associated Symptom in the Acute Treatment of Migraine: the ACHIEVE II Randomized Clinical Trial. JAMA 322(19):1887\u20131898","journal-title":"JAMA"},{"issue":"10","key":"1662_CR86","doi-asserted-by":"publisher","first-page":"e2128544","DOI":"10.1001\/jamanetworkopen.2021.28544","volume":"4","author":"CP Yang","year":"2021","unstructured":"Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, Tang KT, Wang SJ (2021) Comparison of New Pharmacologic Agents with Triptans for treatment of migraine: a systematic review and Meta-analysis. JAMA Netw Open 4(10):e2128544","journal-title":"JAMA Netw Open"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01662-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01662-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01662-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T08:02:07Z","timestamp":1700380927000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01662-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1662"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01662-6","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]},"assertion":[{"value":"27 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}